Growth Metrics

Esperion Therapeutics (ESPR) Debt to Equity (2016 - 2026)

Esperion Therapeutics filings provide 4 years of Debt to Equity readings, the most recent being -$0.5 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 39.0% to -$0.5 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.5, a 39.0% decrease, with the full-year FY2025 number at -$0.5, down 39.0% from a year prior.
  • Debt to Equity hit -$0.5 in Q4 2025 for Esperion Therapeutics, down from -$0.34 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.33 in Q1 2025 to a low of -$0.5 in Q4 2025.